Tobradex ST®
Tobramycin 0.3% / Dexamethasone 0.05% · ophthalmic suspension
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation with superficial bacterial infection or a risk of it
One drop into the conjunctival sac(s) every 4 to 6 hours, increased to one drop every 2 hours during the initial 24 to 48 hours, then tapered; not more than one bottle initially
Global inflammation score is already lower than azithromycin by day 8.
Chronic anterior uveitis, and corneal injury from chemical, radiation, or thermal burns or foreign body penetration
One drop into the conjunctival sac(s) every 4 to 6 hours, increased to one drop every 2 hours during the initial 24 to 48 hours, then tapered; not more than one bottle initially
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
- Hypersensitivity to a component of the medication.
Ophthalmic suspension, tobramycin 0.3% (3 mg/mL) and dexamethasone 0.05% (0.5 mg/mL), 2.5 mL, 5 mL
Tobramycin is an antibacterial that inhibits the growth of bacteria by inhibiting protein synthesis, providing action against susceptible bacteria. Dexamethasone is a potent corticoid. Corticoids suppress the inflammatory response to a variety of agents and can delay or slow healing. Because corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may result in glaucoma with optic nerve damage and defects in visual acuity and visual fields; monitor IOP if this product is used 10 days or longer, and evaluate it before the initial prescription and each renewal.
- Aminoglycoside sensitivity: Sensitivity to topically applied aminoglycosides may occur.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Delayed healing: Steroids after cataract surgery may delay healing and increase the incidence of bleb formation; in diseases causing thinning of the cornea or sclera, perforation has occurred with topical steroids.
- Secondary or masked infection: Prolonged corticosteroid use may suppress host response and increase the hazard of secondary ocular infection, and in acute purulent conditions steroids may mask infection or enhance existing infection; re-evaluate if signs and symptoms fail to improve after 2 days.
- Viral infection exacerbation: Ocular steroids may prolong the course and exacerbate the severity of many viral eye infections, including herpes simplex; a history of herpes simplex requires great caution.
- Fungal infection: Fungal corneal infection is particularly prone to develop with long-term local steroid application, and fungus invasion must be considered in any persistent corneal ulceration where a steroid has been or is in use.
- Renewal examination: The initial prescription and each renewal should follow examination with magnification, such as slit lamp biomicroscopy and where appropriate fluorescein staining.
- Blurred vision: Vision may be temporarily blurred following dosing; care should be exercised in operating machinery or driving a motor vehicle.
- Risk of contamination: Do not touch the dropper tip of the bottle to any surface, as this may contaminate the contents.
- Contact lens wear: The benzalkonium chloride preservative may be absorbed by soft lenses; lenses should not be worn during treatment.
Common Side Effects
Topical ocular tobramycin most often causes hypersensitivity and localized ocular toxicity (eye pain, eyelid pruritus and edema, conjunctival hyperemia) in under 4%. Steroid reactions are increased IOP with possible glaucoma, infrequent optic nerve disorder, subcapsular cataract, and impaired healing. Secondary infection has occurred with steroid-antimicrobial combinations, including fungal keratitis with long-term steroid use and bacterial infection after host response suppression. Headache and increased blood pressure occurred at 0.5% to 1%. Postmarketing reports add anaphylactic reaction and erythema multiforme. Excess dexamethasone may cause Cushing's syndrome and adrenal suppression in predisposed patients, including children and those on CYP3A4 inhibitors. Aminoglycosides may aggravate muscle weakness in known or suspected neuromuscular disorders such as myasthenia gravis.
Pregnancy: Corticosteroids have been shown to be teratogenic in animal studies. Ocular administration of 0.1% dexamethasone, twice this product's strength, produced fetal anomalies in 15.6% and 32.3% of 2 groups of pregnant rabbits, and chronic dexamethasone therapy produced fetal growth retardation and increased mortality in rats; tobramycin up to 100 mg/kg/day in rats and rabbits (equivalent to human doses of 16 and 32 mg/kg/day) revealed no evidence of impaired fertility or harm to the fetus. No adequate and well-controlled studies in pregnant women; prolonged or repeated corticoid use in pregnancy has been associated with an increased risk of intra-uterine growth retardation, and infants of mothers who received substantial corticosteroid doses should be observed for hypoadrenalism. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects; whether topical ocular dosing produces detectable quantities in human milk is not known. Caution should be exercised when this product is administered to a nursing woman.
Safety and effectiveness below age 2 have not been established.